← All organizations
Highest phase reached
Phase 4
First clinical trial
Sep 1, 1995First marketed drug
Jan 1, 1989First NDA
Dec 9, 1991Last known activity
Feb 1, 2002
Acquired by GlaxoSmithKline on Jan 1, 2000
Timeline
1980s
- Jan 1, 1989
SmithKline Beecham— Founded
- Jan 1, 1989
Beecham— Acquired
- Jan 1, 1989
SmithKline Beckman— Acquired
- Dec 1, 1989
prednisone— NDA Secondary Org
1990s
- Feb 14, 1997
hydrocodone— Marketing Organization
2000s
- Jan 1, 2000
GlaxoSmithKline— Acquired By
- May 11, 2001
hepatitis-a virus (inactivated) / hepatitis-b surface antigen— NDA Organization
Drugs by trial phase (171 distinct, 624 trials)
Phase 4 (7 own, 65 via acquisition)
Phase 3 (4 own, 34 via acquisition)
Phase 2 (11 own, 30 via acquisition)
Phase 1 (1 own, 15 via acquisition)
Other trials (0 own, 4 via acquisition)
Indications
Approved for
Studied for
- Carcinoma, Ovarian Epithelial
- Communicable Diseases
- Depression
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Hepatitis
- Hepatitis B
- Hypertension
- Infections
- Insulin Resistance
- Leukemia
- Leukoencephalopathies
- Leukoencephalopathy, Progressive Multifocal
- Lung Neoplasms
- Malaria
- Microsporidiosis
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Ovarian Neoplasms
- Parasitemia
- Plasmacytoma
- Pneumonia
- Pneumonia, Ventilator-Associated
- Protozoan Infections
- Small Cell Lung Carcinoma
Marketed drugs (42)
Subsidiaries (2 direct, 17 total across the full acquisition tree)
- Beecham
- SmithKline Beckman
- Allergan (1948) L2
- C.L. Bencard L2
- International Clinical Laboratories L2
- S.E. Massengill Company L2
- Smith, Kline & French L2
- Allergan L3
- Smith and Shoemaker L3
- Cobalt Labs Inc L4
- Esprit Pharma L4
- John K. Smith and Company L4
- MAP Pharmaceuticals L4
- Oculex Pharmaceuticals L4
- Oculinium L4
- Skinmedica L4
- Vicept Therapeutics L4
Recent trials (16)
- NCT01039025CollaboratorPhase 2Feb 1, 2002
- NCT00018759CollaboratorPhase 4Mar 1, 2001
- NCT00032487CollaboratorPhase 3Dec 1, 2000
- NCT02526615CollaboratorPhase 4Oct 1, 2000
- NCT02488980CollaboratorPhase 2May 1, 2000
- NCT00002191Lead sponsorPhase 3Nov 2, 1999
- NCT00002395Lead sponsorPhase 2Nov 2, 1999
- NCT00005793CollaboratorPhase 1/Phase 2Jul 1, 1999
- NCT00003917CollaboratorPhase 3Mar 1, 1999
- NCT02488902CollaboratorPhase 2Aug 1, 1998
- NCT00100477CollaboratorPhase 2Aug 1, 1998
- NCT00005792CollaboratorPhase 1Jun 2, 1998
- NCT01559753CollaboratorPhase 4Jan 1, 1998
- NCT00003733Lead sponsorPhase 2Dec 1, 1997
- NCT02491606CollaboratorPhase 2May 1, 1997
Details
- Founded
- London, GB Jan 1, 1989
- First NDA
- Dec 9, 1991
- Last known activity
- Feb 1, 2002
Designations held
- Orphan drug
- Priority review